908373-50-2

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 455-37-8 3-fluorobenzamide 
• 105983-77-5 methyl 4-bromo-3-oxopentanoate 

Downstream Products

• 1017369-15-1 C₁₂H₁₀FNO₃ 
• 851181-30-1 2-(2-(3-fluorophenyl)-5-methyloxazol-4-yl)ethanol 
• 1027058-38-3 4-{2-[2-(3-Fluoro-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-benzaldehyde 

Relevant academic research and scientific papers

Synthesis and evaluation of a series of benzopyran derivatives as PPAR α/γ agonists

A series of benzopyran derivatives were synthesized and evaluated for PPAR α/γ agonist activities. Most of the compounds exhibit reasonable PPAR α and PPAR γ agonist activities. In particular, compounds 7b, 8b, 8e and 8h with remarkable PPARg EC50 values of 0.001 μM are excellent full PPAR γ agonists with the functional potency about 130, 20 times stronger than that of leading compound 5 and rosiglitazone, respectively. Compounds 7a, 7c, 7d and 8a are dual PPAR α/γ agonists, and all of them gave comparable or stronger PPAR α/γ agonist efficacy than that of the corresponding positive control.

Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5- lipoxygenase

Azole phenoxy hydroxyureas are a new class of 5-lipoxygenase (5-LO) inhibitors. Structure-activity relationship studies have demonstrated that electronegative substituents on the 2-phenyl portion of the oxazole tail increased the ex vivo potency of these